Johnson & Johnson stock holds as 2025 revenue reached $88.8 billion

Johnson & Johnson (US4781601046) stock is anchored by 2025 revenue of $88.8 billion, net earnings of $14.7 billion, and adjusted diluted EPS of $10.62, while the shares traded at $163.18 as of 22 July 2026. The company reported those figures in its 2025 annual results, and the scale of the business still gives the stock a defensive earnings base.

2025 revenue near $88.8 billion

Revenue for fiscal 2025 reached $88.8 billion, up from $88.8 billion? Not used. The cleaner comparison is that management reported $88.8 billion in 2025 revenue alongside net earnings of $14.7 billion, which underlines the size of the earnings stream. Adjusted diluted EPS came in at $10.62 for 2025, a useful yardstick for how the company is translating sales into shareholder profit.

The mix matters as much as the headline revenue number. Johnson & Johnson's 2025 income profile shows why the stock often trades on earnings durability rather than one-off growth bursts.

$14.7 billion profit base

Net earnings of $14.7 billion in 2025 give the company a large earnings cushion, and that remains central for valuation work. The comparison point is the same fiscal year: revenue of $88.8 billion against net earnings of $14.7 billion shows a meaningful profit conversion scale.

Adjusted diluted EPS of $10.62 in 2025 adds another metric investors track, because it strips out some one-time items and gives a clearer operating view. For a stock of this size, that figure is often more useful than a single quarter alone.

Shares at $163.18

Johnson & Johnson shares traded at $163.18 as of 22 July 2026, giving the stock a current market reference against last reported full-year earnings. That price sits alongside the 2025 revenue base of $88.8 billion and net earnings of $14.7 billion, which keeps the comparison between market value and profit generation visible.

The market backdrop matters because the stock is not trading on a story alone. It is trading on a long record of reported revenue, earnings, and cash-generating capacity.

Medical products remain central

The company's product mix still revolves around pharmaceuticals, medical technology, and consumer health history, but the market usually keys off the largest revenue engines rather than the legacy brand story. In 2025, the reported $88.8 billion revenue base and $10.62 adjusted EPS are the numbers that best frame that business mix.

For investors reading the stock through a product lens, the point is simple: the broad healthcare portfolio supports a diversified earnings profile, and that shows up in the full-year numbers more clearly than in any single product headline.

Market level and filing context

At $163.18 as of 22 July 2026, Johnson & Johnson stock has a live market reference that can be set against the latest full-year results. The comparison is straightforward: $88.8 billion of 2025 revenue, $14.7 billion of 2025 net earnings, and $10.62 of adjusted diluted EPS give the share price a concrete earnings backdrop.

That combination is what matters most for a large-cap healthcare name. The stock is being read through earnings scale, not through a single event headline.